CION Ameerpet
Anaplastic astrocytoma is a grade 3 brain tumour. The diagnosis is frightening, but the right tests change everything. At CION, your IDH and molecular results guide a coordinated, transparent plan.
An anaplastic astrocytoma is a malignant brain tumour that grows from astrocytes — the star-shaped support cells that hold the brain together. The word "anaplastic" simply means the cells look abnormal and are dividing actively when a pathologist examines them under a microscope.
Brain tumours are not "staged" like other cancers. Instead, they are given a WHO grade from 1 to 4, based on how aggressive the cells look. Anaplastic astrocytoma is a grade 3 tumour — it sits between the slow-growing grade 2 astrocytoma and the fastest-growing grade 4 glioblastoma (GBM). It is most often diagnosed in adults aged 30 to 50.
Because the cells spread finger-like into surrounding healthy brain, surgery alone usually cannot remove every cell. That is why treatment for a grade 3 astrocytoma normally combines surgery, radiation and chemotherapy — and why a single molecular result, the IDH status, matters more than almost anything else. This page is part of CION's wider guide to astrocytoma and its grades.
Under the 2021 WHO classification of central-nervous-system tumours, an astrocytoma is graded and named by its IDH status. A grade 3 astrocytoma with an IDH mutation is formally called "astrocytoma, IDH-mutant, grade 3" — and IDH-mutant gliomas have a meaningfully better outlook than IDH wild-type tumours of the same grade. (Source: WHO Classification of Tumours of the CNS, 5th edition, 2021; EANO guidelines on diffuse gliomas.)
Both are malignant gliomas, and they share the same treatment building blocks. But the differences in how they grow — and who they affect — are real, and they shape the plan and the outlook.
Grows moderately fast. Under the microscope, the cells divide actively but there is no necrosis (dead tissue) and no abnormal new blood vessels. More common in younger adults (30–50). Many carry an IDH mutation, which signals a more favourable course. Treated with surgery, radiation and chemotherapy.
Grows fastest of all gliomas. Defined by necrosis and abnormal blood-vessel growth under the microscope. More common after age 60. More often IDH wild-type. Treated with surgery, then concurrent chemoradiation and chemotherapy. Read more on the brain tumour treatment page.
An IDH wild-type grade 3 astrocytoma can behave like a glioblastoma, which is why molecular testing — not the microscope alone — settles the final diagnosis and grade.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
You deserve a clear, coordinated plan — not a rushed decision. We walk this journey with you, from molecular testing to treatment, with transparent costs.
The diagnosis is built in two steps: an image and a tissue sample. Imaging suggests the tumour; only the tissue confirms the exact type, grade and molecular profile.
MRI with gadolinium contrast is the gold standard. It shows the tumour's location, size and relationship to critical areas controlling speech and movement. Grade 3 tumours often show some contrast uptake but usually lack the ring-like pattern typical of glioblastoma. Specialised sequences — perfusion and spectroscopy — add information about how active the tumour is.
A tissue sample is essential. It comes either from surgical removal of the tumour or from a stereotactic needle biopsy for tumours in deep or risky locations. At CION, all neurosurgery — including stereotactic biopsy and craniotomy — is coordinated with accredited neurosurgical partners; CION does not perform neurosurgery in-house. The sample is then read by a neuropathologist and sent for molecular testing.
For a grade 3 astrocytoma, the molecular results are as important as the grade itself. Three markers, all read from the same biopsy sample, shape both the diagnosis and the treatment.
IDH is the most powerful prognostic marker in glioma. An IDH-mutant grade 3 astrocytoma grows more slowly and has a meaningfully better outlook than an IDH wild-type tumour of the same grade. An IDH wild-type grade 3 astrocytoma may be reclassified and managed more like a glioblastoma. This single result can change the whole conversation.
This marker separates an astrocytoma from an oligodendroglioma. By definition, a true astrocytoma does not have the 1p/19q co-deletion. Testing for it prevents a tumour from being mislabelled — important because oligodendrogliomas respond differently to chemotherapy.
MGMT is a DNA-repair gene. When it is "methylated" (switched off), the tumour is more sensitive to alkylating chemotherapy. Knowing MGMT status helps the medical oncology team predict how well chemotherapy is likely to work. CION arranges IDH, 1p/19q and MGMT testing as standard on every malignant glioma biopsy — in line with NCCN and EANO guidance.
Treatment combines three modalities, sequenced by your molecular results and reviewed by CION's multidisciplinary tumour board before anything begins.
CION also delivers steroid and antiseizure management, supportive care and rehabilitation (speech therapy, physiotherapy, cognitive support) directly. Stereotactic radiosurgery and any specialist neurosurgical procedures are arranged as part of coordinated care with partner facilities — these are not claimed as in-house units.
Want this explained for your specific reports? Book a free consultation or call 18002028726.
There is no single survival number for a grade 3 astrocytoma, and any figure you read should be treated as a range, not a promise. Outcomes depend most on:
Published series from NCCN and EANO report median survival for IDH-mutant grade 3 astrocytoma often in the range of several years, while IDH wild-type tumours behave more aggressively. Importantly, older statistics can understate today's outcomes because they predate routine molecular testing and modern chemoradiation. The most honest, personal estimate comes only after your full pathology and molecular results are reviewed by a tumour board.
A grade 3 astrocytoma can, over time, transform into a higher-grade tumour that behaves like grade 4 glioblastoma. That is why follow-up MRI scans — often every 2 to 3 months early on — are part of care, and why the team carefully separates true progression from harmless post-treatment inflammation before changing any plan. (Source: NCCN Central Nervous System Cancers guidelines; EANO guidelines on diffuse gliomas.)
A second opinion is especially worthwhile for a grade 3 astrocytoma if any of these apply:
CION offers a free written second opinion with no obligation to start treatment. Decisions here are made for healing, not billing. Explore the full brain cancer & tumour hub, the brain tumour treatment page, or learn more about astrocytoma and its grades. Book your free consultation today.
Get a free written second opinion from CION's tumour board — especially valuable if IDH, 1p/19q or MGMT testing was not done on your biopsy.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Anaplastic astrocytoma is a grade 3 astrocytoma — a malignant brain tumour that grows from the brain's star-shaped support cells (astrocytes). On the WHO scale of grade 1 to grade 4, it sits between slow-growing grade 2 gliomas and the fastest grade 4 glioblastoma. It is "anaplastic" because the cells look abnormal and divide actively under the microscope. Most are diagnosed in adults aged 30 to 50. Because the cells spread into surrounding brain tissue, treatment usually combines surgery, radiation and chemotherapy rather than surgery alone. The single most important detail is the tumour's IDH status, which shapes both the modern name and the outlook.
Both are malignant gliomas, but grade 3 anaplastic astrocytoma generally grows more slowly than grade 4 glioblastoma (GBM) and tends to occur in younger adults. Under the microscope, grade 3 tumours show active cell division but lack the dead tissue (necrosis) and abnormal new blood vessels that define grade 4. The treatment building blocks overlap — surgery, radiation and chemotherapy — but the sequence and the chemotherapy choice can differ. Outlook is also typically more favourable than GBM, especially when the tumour carries an IDH mutation. A neuropathology re-read and molecular testing settle the exact grade and type.
IDH (isocitrate dehydrogenase) is a gene tested on the biopsy sample. In gliomas, an IDH mutation is the single most powerful prognostic marker. Under the 2021 WHO classification, a grade 3 astrocytoma with an IDH mutation is named "astrocytoma, IDH-mutant, grade 3", and these tumours grow more slowly and have meaningfully longer survival than IDH wild-type tumours at the same grade. An IDH wild-type grade 3 tumour may behave more like a glioblastoma and is graded and managed accordingly. This is why IDH testing — alongside 1p/19q and MGMT — should be done on every malignant glioma biopsy before a treatment plan is set.
Prognosis varies widely and depends mostly on IDH status, age, how much tumour was safely removed, and overall fitness. Published series report median survival for IDH-mutant grade 3 astrocytoma often in the range of several years, while IDH wild-type tumours behave more aggressively. NCCN and EANO frame these as ranges, not guarantees — some people live well beyond the averages. Numbers from older studies can understate today's outcomes because they predate routine molecular testing and modern chemoradiation. The most honest answer comes after your full pathology and molecular results, discussed by a tumour board. Ask CION's neuro-oncology team for a plain-language review of your reports.
Treatment is built around three pillars. First, maximum safe tumour removal — coordinated with accredited neurosurgical partners, as CION does not perform neurosurgery in-house. Second, radiation therapy (IMRT/IGRT) delivered directly by CION's radiation oncology team to the tumour bed. Third, chemotherapy — typically alkylating chemotherapy — managed by CION's medical oncology team. Molecular testing (IDH, 1p/19q, MGMT) guides the exact sequence and drug choice. CION also delivers steroid and seizure management, supportive care and rehabilitation directly. Every case is reviewed by a multidisciplinary tumour board before treatment begins.
Yes — over time a grade 3 anaplastic astrocytoma can transform into a higher-grade tumour, behaving like grade 4 glioblastoma. This is why follow-up after treatment is important: regular MRI scans (often every 2 to 3 months early on) watch for change. If a follow-up scan looks different, the team distinguishes true progression from treatment-related inflammation before changing the plan. Knowing the IDH status from the start helps predict how likely and how quickly transformation may occur. If you have already been treated and a recent scan has changed, a second opinion can confirm whether the finding is genuine progression. Talk to a specialist if you are unsure.
A second opinion is especially valuable for grade 3 astrocytoma in three situations: if molecular testing (IDH, 1p/19q, MGMT) was not done on your biopsy — these results can change both the diagnosis and the plan; if the exact grade is uncertain on the original report and would benefit from a neuropathology re-read; and if surgery, radiation and chemotherapy have not all been discussed as a coordinated plan. CION offers a free written second opinion — bring your MRI, biopsy report and any molecular results. There is no obligation to start treatment with us. Learn more about astrocytoma and its grades.
Browse our complete guide to brain tumours and brain cancer — symptoms, scans, tumour types, treatment, prognosis and life after treatment. Tap any topic to read more.